Company Therapeutic Solutions International, Inc.

Equities

TSOI

US8833781011

Medical Equipment, Supplies & Distribution

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Medical Devices & Implants

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Market Closed - OTC Markets Other stock markets 01:29:04 19/06/2024 am IST			5-day change	1st Jan Change
0.0007 ^USD	-12.50%		-22.22%	-30.00%

30/05	Therapeutic Solutions International, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
17/04	Therapeutic Solutions International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Therapeutic Solutions International, Inc. is focused on immune modulation for the treatment of several specific diseases. The Company is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, and traumatic brain injury (TBI), and for daily health. Its flagship product, QuadraMune, is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechin gallate, and thymoquinone. Its synergistic blend of ingredients helps the immune system fight off common and complex ailments and promotes healthy T Cell activity. It has developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body's natural killer (NK) cells. It has obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE), TBI, and lung pathology.

Number of employees: 3

USD in Million	2022	Weight	2023	Weight	Delta
Immune Modulation 100.0 %	0	100.0 %	0	100.0 %	-52.12%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	0	100.0 %	0	100.0 %	-52.12%

Managers	Title	Age	Since
Timothy Dixon CEO	Chief Executive Officer	66	31/11/31
James Veltmeyer CTO	Chief Tech/Sci/R&D Officer	59	18/18/18
Feng Lin CTO	Chief Tech/Sci/R&D Officer	54	03/19/03
Famela Ramos PRN	Corporate Officer/Principal	48	-
Serena Robella SAM	Sales & Marketing	-	12/20/12

Members of the board	Title	Age	Since
Thomas Ichim BRD	Director/Board Member	49	22/16/22
Timothy Dixon CEO	Chief Executive Officer	66	31/11/31

	Vote	Quantity	Free-Float	Total Float
Stock A	0	1,000	0	79.12 %
Stock B	1	4,591,517,624	3,632,884,046 ( 79.12 %)
Stock C	0	2	0

Name	Equities	%	Valuation
Timothy Dixon 10.62 %	449,350,245	10.62 %	449 350 $
John Peck 5.373 %	227,283,333	5.373 %	227 283 $
Thomas Ichim 4.184 %	177,000,000	4.184 %	177 000 $
Jadi Cell LLC 3.106 %	131,402,390	3.106 %	131 402 $
Feng Lin 1.466 %	62,000,000	1.466 %	62 000 $
James Veltmeyer 0.8747 %	37,000,000	0.8747 %	37 000 $
Famela Ramos 0.1418 %	6,000,000	0.1418 %	6 000 $
Strategic Investment Solutions, Inc. (Illinois) 0.000071 %	3,000	0.000071 %	3 $

Therapeutic Solutions International, Inc.

701 Wild Rose Lane

83525, Elk

http://www.therapeuticsolutionsint.com

address Therapeutic Solutions International, Inc.(TSOI)

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Medical Equipment, Supplies & Distribution

Medical Devices & Implants

	1st Jan change	Capi.
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.	-30.00%	32.47L
STRYKER CORPORATION	+16.43%	13TCr
SMITH & NEPHEW PLC	-7.48%	1.1TCr
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-12.07%	766.26Cr
GLAUKOS CORPORATION	+42.65%	570.8Cr
INSPIRE MEDICAL SYSTEMS, INC.	-20.18%	482.45Cr
AXONICS, INC.	+8.48%	344.43Cr
ENOVIS CORPORATION	-20.37%	244.69Cr
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-18.39%	191.26Cr
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-16.75%	184.69Cr

Medical Devices & Implants